HALO · Halozyme Therapeutics, Inc.

Halozyme’s Q1 2026 results reflect robust execution across its core royalty-driven business model, with total revenue rising 42% YoY to $376.7 million and royalty revenue surging 43% to $240.7 million — both figures exceeding prior-year levels by wide margins and validating continued uptake of ENHANZE-enabled products like DARZALEX Faspro, VYVGART Hytrulo, and Phesgo. The 42% revenue growth was explicitly attributed to royalty expansion and increased API product sales, while cost of sales rose proportionally ($79.2M vs. $48.4M) due to higher bulk rHuPH20 shipments. Operating income grew 30% YoY to $184.5 million, and Adjusted EBITDA jumped 42% to $229.5 million, underscoring operating leverage despite elevated R&D and SG&A expenses tied to recent acquisitions (Elektrofi and Surf Bio). Management reaffirmed full-year 2026 guidance ranges — notably $1.710–$1.810 billion total revenue and $1.130–$1.170 billion royalty revenue — which implies sustained royalty acceleration and reinforces visibility into multi-year growth. Critically, the company launched a $1 billion share repurchase program with $400 million targeted for 2026, directly linking strong cash generation ($320.9M cash balance as of March 31, 2026, up from $145.4M at year-end) to shareholder return. Strategic momentum accelerated with three new Hypercon™ agreements (Vertex, Oruka, GSK) and nine ENHANZE products now in clinical development — positioning Halozyme not only for near-term royalty growth but also for durable, multi-decade royalty waves beginning in the 2030s. This combination of financial outperformance, capital return, and deepening platform adoption elevates Halozyme’s profile as a high-conviction, cash-generative biotech infrastructure play.